Spain· ES:1231730001
BRIUMVI 150 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
A medicinal product containing ublituximab, registered in Spain by Neuraxpharm Pharmaceuticals S.L..
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- ublituximab
- Manufacturer
- Neuraxpharm Pharmaceuticals S.L.
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ublituximab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBRIUMVINeuraxpharm Pharmaceuticals, S.L., Barcelona
- SwitzerlandBriumvi
- United KingdomBriumvi 150mg/6ml concentrate for solution for infusion vialsNeuraxpharm UK Ltd
- IrelandBriumvi 150 mg Concentrate for solution for infusionNeuraxpharm Pharmaceuticals S.L.
- IcelandBriumviNeuraxpharm Pharmaceuticals S.L.
- NetherlandsBriumvi 150 mg concentraat voor oplossing voor infusieNeuraxpharm Pharmaceuticals S.L.
- NorwayBriumviNeuraxpharm Pharmaceuticals, S.L.
- PolandBriumviNeuraxpharm Pharmaceuticals, S.L.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Briumvi
- Liechtenstein · Briumvi
- Norway · Briumvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/87fa3b4f-9dd1-4b1d-86e4-020dfee90d6c GET /v1/drugs/87fa3b4f-9dd1-4b1d-86e4-020dfee90d6c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":1699962527000}",
"nregistro": "1231730001",
"substance": "ublituximab"
}See everything about ublituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.